Produção Nacional
Revisado por pares
Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies
2005; Elsevier BV; Volume: 297; Issue: 1-2 Linguagem: Inglês
10.1016/j.ijpharm.2005.03.002
ISSN1873-3476
AutoresEunice Kazue Kano, Cristina Helena dos Reis Serra, Eunice Emiko Mori Koono, Simone Schramm Andrade, Valentina Porta,
Tópico(s)Biochemical and Molecular Research
ResumoA simple, accurate, precise and sensitive high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed to quantificate lamivudine (3-TC) in human plasma samples from bioequivalence studies. 3-TC and stavudine (internal standard, I.S.) were extracted from 0.5 ml of human plasma by acetonitrile protein precipitation. The method was validated over a concentration range of 0.05–3.00 μg/ml and used in a bioequivalence trial between two lamivudine formulations, to assess its usefulness in this kind of study. FURP–lamivudine (Fundação para o Remédio Popular, Brazil, as test formulation) and Epivir® (GlaxoSmithKline, Brazil, as reference formulation) were evaluated following a single 150 mg oral dose to 24 healthy volunteers of both genders. The dose was administered after an overnight fast according to a two-way crossover design. Bioequivalence between the products was determined by calculating 90% confidence intervals (90% CI) for the ratio of Cmax, AUC0−t and AUC0−inf values for the test and reference products, using logarithmic transformed data. The 90% confidence intervals for the ratio of Cmax (0.86–1.06), AUC0−t (0.96–1.04) and AUC0−inf (0.97–1.05) values for the test and reference products are within the 0.80–1.25 interval proposed by FDA and EMEA. It was concluded that the two 3-TC formulations are bioequivalent in their rate and extent of absorption, and thus, may be used interchangeably.
Referência(s)